Equities
  • Price (EUR)0.530
  • Today's Change0.00 / 0.00%
  • Shares traded4.81k
  • 1 Year change-52.68%
  • Beta2.0278
Data delayed at least 15 minutes, as of Feb 16 2026 07:12 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PolyNovo Limited is an Australia-based medical technology company. The Company’s business includes designing, manufacturing and selling biomedical devices. Its principal activity is the development of medical devices for medical applications, utilizing the patented bioabsorbable polymer technology NovoSorb. NovoSorb is a family of proprietary medical grade polymers that can be utilized to manufacture medical devices designed to support tissue repair. NovoSorb polymer devices can be expressed in a variety of physical formats including foam, coatings, fibers, plastic structures, films, and biologic carriers. Its products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a bilayer dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb MTX has applicability for single stage grafting in burns, chronic, and surgical wounds.

  • Revenue in AUD (TTM)127.73m
  • Net income in AUD13.21m
  • Incorporated1998
  • Employees301.00
  • Location
    Polynovo Ltd2/320 Lorimer StreetMELBOURNE 3207AustraliaAUS
  • Phone+61 80095-8289
  • Fax+61 38681-4099
  • Websitehttps://polynovo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.